Brief: Zentalis Pharmaceuticals Announces First Patient Dosed In Aspenova Phase 3 Trial Of Azenosertib In Patients With Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
05/05/2026 13:01
May 5 (Reuters) - Zentalis Pharmaceuticals Inc ZNTL.O: ZENTALIS PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN ASPENOVA PHASE 3 TRIAL OF AZENOSERTIB IN PATIENTS WITH CYCLIN E1-POSITIVE PLATINUM-RESISTANT OVARIAN CANCER ZENTALIS PHARMACEUTICALS INC - EXPECTS DENALI PART 2 TOPLINE READOUT BY YEAR-END 2026 Source text: ID:nGNX9WpXQN Further company coverage: ZNTL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zentalis Pharmaceuticals
See all newsBrief: Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc
Brief: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer